PCL. Inc
241820KOSDAQPharmaceuticals
PCL. Inc (241820, KOSDAQ) — reported financials from Korean regulatory filings.
Reported financials
Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.
| Year | Revenue | Operating profit | Net profit | Assets | Equity | Basis |
|---|---|---|---|---|---|---|
| 2021 | 46 | -26 | -32 | 79 | 17 | Consolidated |
| 2022 | 37 | -8 | -4 | 88 | 34 | Consolidated |
| 2023 | 8 | -16 | -20 | 62 | 38 | Consolidated |
| 2024 | 1 | -27 | -53 | 22 | 7 | Consolidated |
| 2025 | — | — | — | — | — | — |
Ratios, year by year
Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.
| Year | Operating margin | Net margin | Equity / assets | Return on equity |
|---|---|---|---|---|
| 2021 | -55.8% | -68.6% | 21% | -190.5% |
| 2022 | -22.2% | -10.8% | 38.3% | -11.9% |
| 2023 | -191.4% | -240.6% | 60.5% | -53.9% |
| 2024 | -2,175.4% | -4,240.5% | 33% | -742.6% |
| 2025 | — | — | — | — |
Revenue moved -97.3% between 2021 and 2025.
Net profit was negative in the 4 most recent consecutive years on file. Counted from the 4 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.
These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.
When it was founded
The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.
| Incorporated |
|---|
Other companies in Pharmaceuticals
181 listed companies file under this classification. Showing 12.